Hannover Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2024

  1. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

    Blood, Vol. 144, Núm. 12, pp. 1257-1270

2023

  1. Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

    British Journal of Haematology, Vol. 200, Núm. 2, pp. 170-174

2022

  1. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

    Leukemia, Vol. 36, Núm. 1, pp. 90-99

2021

  1. Adjunctive Volasertib in Patients with Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

    HemaSphere, Vol. 5, Núm. 8, pp. E617

  2. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    Leukemia, Vol. 35, Núm. 9, pp. 2539-2551

2020

  1. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Blood, Vol. 135, Núm. 5, pp. 371-380

  2. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia

    Scientific Reports, Vol. 10, Núm. 1

  3. Reduced SLIT2 is associated with increased cell proliferation and arsenic trioxide resistance in acute promyelocytic Leukemia

    Cancers, Vol. 12, Núm. 11, pp. 1-16

2019

  1. Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia

    Blood, Vol. 134, Núm. 12, pp. 951-959

2017

  1. Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia

    Blood Advances, Vol. 1, Núm. 21, pp. 1807-1814

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation

    New England Journal of Medicine, Vol. 377, Núm. 5, pp. 454-464

  4. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

    Annals of Hematology, Vol. 96, Núm. 9, pp. 1449-1456

2015

  1. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

    Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356

  2. High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

    Blood, Vol. 126, Núm. 20, pp. 2302-2306

2014

  1. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

    Annals of Hematology, Vol. 93, Núm. 12, pp. 2001-2010

  2. Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: An International Consortium on Acute Promyelocytic Leukaemia study

    British Journal of Haematology, Vol. 166, Núm. 4, pp. 540-549

2013

  1. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL

    Blood, Vol. 121, Núm. 11, pp. 1935-1943

2012

  1. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT

    Leukemia, Vol. 26, Núm. 6, pp. 1211-1217

2005

  1. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes

    Bone Marrow Transplantation, Vol. 35, Núm. 1, pp. 37-43